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Department of Biochemistry, Stanford University School of Medicine, Stanford, CaliforniaABSTRACT With the advent of technologies to obtain the complete sequence of the human genome in a cost-effective
manner, this decade and those to come will see an exponential increase in our understanding of the underlying genetics that
lead to human disease. And where we have a deep understanding of the biochemical and biophysical basis of the machineries
and pathways involved in those genetic changes, there are great hopes for the development of modern therapeutics that spe-
cifically target the actual machinery and pathways altered by individual mutations. Prime examples of such a genetic disease are
those classes of hypertrophic and dilated cardiomyopathy that result from single amino-acid substitutions in one of several of the
proteins that make up the cardiac sarcomere or from the truncation of myosin binding protein C. Hypertrophic cardiomyopathy
alone affects ~1 in 500 individuals, and it is the leading cause of sudden cardiac death in young adults. Here I describe
approaches to understand the molecular basis of the alterations in power output that result from these mutations. Small mole-
cules binding to the mutant sarcomeric protein complex should be able to mitigate the effects of hypertrophic and dilated car-
diomyopathy mutations at their sources, leading to possible new therapeutic approaches for these genetic diseases.INTRODUCTIONAfter 40 years of developing and utilizing assays to under-
stand the molecular basis of energy transduction by the
myosin family of molecular motors (1–3), all members of
my laboratory are now focused on understanding the under-
lying biochemical and biophysical basis of hypertrophic and
dilated cardiomyopathies. Hypertrophic cardiomyopathy
(HCM) is most often a result of single missense mutations
in one of several sarcomeric proteins, the sarcomere being
the fundamental contractile unit of the cardiomyocyte.
HCM has been shown to be a monogenic inherited disease
(4), although the effects of secondary mutations and envi-
ronmental factors on the penetrance of the disease are
important areas of research (5–7).
Clinically, HCM is characterized by an asymmetric thick-
ening of the ventricular walls and a decrease in the ventric-
ular chamber size that occurs without a predisposing cause.
In addition, fibrosis of the cardiac muscle and cardiomyo-
cyte disarray are associated with the disease (8). Systolic
performance of the heart is preserved but relaxation capacity
is diminished. HCM is not a rare disease. It affects ~1 in 500
individuals (8–10). A related genetic disease, idiopathic
dilated cardiomyopathy (DCM), also results from single
missense mutations in some of the same sarcomeric pro-Submitted November 25, 2013, and accepted for publication February 4,
2014.
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Open access under CC BY-NC-ND license.teins, but leads to ventricular chamber dilation and reduced
systolic performance, rather than hypertrophy (11,12).
Associated with HCM and DCM worldwide are heart fail-
ure, arrhythmias, and sudden cardiac death at any age.
This review focuses on HCM and DCM resulting from
single residue changes in the sarcomeric proteins. Some
HCM, and approximately half of familial DCM, are associ-
ated with mutations in nonsarcomere genes, which are not
discussed here. This review also does not include the syn-
dromic myopathies like Duchenne.
The laboratories of Christine and Jon Seidman, more than
20 years ago, showed that a mutation (R403Q) in human
b-cardiac myosin leads to HCM (13). Today, as a result
of their work and that of others, there are reported to
be >300 pathogenic mutations in b-cardiac myosin alone
(14–16), and most of these are in the globular head domain
(subfragment 1 of myosin, or S1) (Fig. 1 a). S1, which is the
motor domain of the myosin molecule (17), has been
crystallized in a wide variety of nucleotide states (18–24),
and its light-chain binding region serves as a lever arm
to amplify movements of the converter domain during the
power-stroke of the head (20–23,25–28). Structurally, the
myosin head domain consists of several subdomains that
are suggested to move mainly as semirigid bodies during
the chemomechanical cycle (22). A primary focus of my
laboratory is on the HCM- and DCM-causing mutations in
human b-cardiac myosin S1, and the discussion here relates
to those studies.
HCM- and DCM-causing mutations occur in other sarco-
meric proteins as well, including tropomyosin and the three
troponin subunits, troponins T, I, and C, the Ca2þ-regulatory
proteins of the sarcomere. Mutations in these thin filamenthttp://dx.doi.org/10.1016/j.bpj.2014.02.011
FIGURE 1 The myosin motor domain, the force-
velocity curve, and power output. (a) Image of
the poststroke state crystal structure of a muscle
myosin motor domain (cardiac human myosin
S1dC, b-isoform complexed with Mn-AMPPNP.
V. A. Klenchin, J. C. Deacon, A. C. Combs, L. A.
Leinwand, and I. Rayment; 4DB1 crystal structure
in the RCSB database. Mutation information is
from the MYOMAPR database; Buvoli 08 is the
reference for those). The actin-binding, converter,
and lever-arm domains are indicated. The length
of the globular head from the actin-binding domain
to the end of the converter is 9 nm, and from the end
of the converter to the end of the lever arm is 8 nm.
Representatives of reported HCM mutations (red
dots) and DCM mutations (blue dots) are shown
(14). (b) The hyperbolic solid line (open circles)
refers to how the velocity changes as a function
of the load imposed on the contractile machinery.
The shape of the curve depends on how much force
the contractile machinery can produce. At any
velocity along the curve, the ensemble force of
the system matches the equal and opposite load
imposed. Power output is the force times the velocity at every point along the curve (dashed line, solid circles). (Gray zone) Region of high power output.
(c) The higher force-producing hypercontractile-causing mutant forms of the contractile apparatus (solid red F-v curve; dashed red power curve) require
more load to slow the contraction, and a higher power-output results. The reverse is expected for the hypocontractile-causing mutant forms (solid blue
F-v curve; dashed blue power curve). (d) The force-velocity curve can be changed in two fundamental ways by hypercontractile-causing mutations: 1),
The force can be increased (solid red F-v curve), resulting in increased power output (dashed red curve). 2), The velocity can be increased even in the absence
of any force change (solid green curve), also resulting in increased power output (dashed green curve). Hypercontractile-causing mutations can also, of
course, lead to changes in both ensemble force and velocity. To see this figure in color, go online.
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pathic DCM cases (29,30). The actin, myosin, tropomyosin,
troponin six-component system is the fundamental Ca2þ-
regulated complex of the sarcomere. There are, however,
additional regulatory elements, such as myosin binding pro-
tein C and titin; mutations in myosin binding protein C are a
frequent cause of HCM (4) and mutations in titin are a prev-
alent cause of DCM (31–33). Much of what I discuss below
applies to these nonmyosin sarcomeric mutations as well as
to those in human b-cardiac myosin S1.FUNDAMENTAL PARAMETERS OF THE CARDIAC
CONTRACTILE SYSTEM
Power is the product of force and velocity of contraction,
and the force-velocity curve is a fundamental functional
aspect of cardiac muscle function (34) (Fig. 1 b). The force
axis on this curve is related to the load on the muscle; the
force the muscle produces must overcome the load. Ventric-
ular function is influenced by two types of loads that are
applied to cardiac muscle. One is the preload, which is the
load applied by the volume of blood in the left ventricle
that results in stretching of the myofibers before the initia-
tion of ejection. According to the Frank-Starling law, in-
crease in ventricular filling increases contractility, and one
major hypothesis is that increase in sarcomere length
activates Ca2þ responsiveness in the Ca2þ-regulated thin
filament (35), but the Frank-Starling effect remains to be
clearly understood at the molecular level. The other loadthat is applied to the ventricle is the pressure in the systemic
circulation during contraction when the aortic valve is open,
called ‘‘afterload’’. The afterload is the primary load that the
heart needs to overcome to eject blood out of the left
ventricle, and is also the load mentioned in the F-v curves
shown in Fig. 1, which depict the relationship between
the velocity of the contracting muscle and the opposing
load applied to the muscle. This review focuses on the
biomechanical aspects of the myosin-actin interaction. Its
regulation by thin filament components is also critical in
determining myocardial contractility, as briefly discussed
below.
Note that there is a fairly broad region of the F-v curve
where the power output is near maximum (>80% power is
maintained between velocities of 20–60% maximum veloc-
ity) (gray zone, Fig. 1 b). HCM patients present with clinical
features of hyperdynamic ventricular function, as suggested
by physical exam and echocardiographic findings (4). Thus,
the HCM heart is recognized as hypercontractile (red F-v
curve, Fig. 1 c), suggesting that the power output is higher
than that of the normal heart. Conversely, the clinical features
of DCM patients are characterized by reduced systolic func-
tion causing hypoperfusion of the body circulation. Hence,
DCM is recognized as hypocontractile (blue F-v curve,
Fig. 1 c), leading to lower power output than that of the
normal heart. Thus, the simplest view is that there are two
mechanistic buckets for changes in power output at the
molecular level, mutations resulting in an increase in power
(hypercontractile) and a decrease in power (hypocontractile),Biophysical Journal 106(6) 1236–1249
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reducing the power output or increasing it, respectively, to
normalize the effect of the mutation and then allowing the
heart to remodel. Life, however, is not that simple.
First of all, the relationships between the hypercontractile
HCM heart and the hypocontractile DCM heart with the
fundamental power outputs of the contractile molecular
machinery making up the sarcomere, at the earliest stages
before apparent clinical symptoms, remain to be clarified.
Thus, the hypothesis that HCM is hypercontractile at
the fundamental molecular level of a sarcomere whereas
DCM is hypocontractile—although a common view (for
reviews, see the literature (36–40))—remains to be estab-
lished as a general paradigm. These mutations have not
been able to be easily studied in the context of purified
human b-cardiac myosin because there has not been an
adequate expression system for preparing homogeneous pu-
rified human b-cardiac myosin in the laboratory. Consistent
with this hypothesis, however, studies of mouse models of
HCM and DCM and with purified mouse cardiac myosin
suggest that HCM cardiomyopathy mutations cause hyper-
contractility whereas DCM cardiomyopathy mutations
cause hypocontractility (41,42). However, these mutations
were studied in the context of the mouse a-cardiac myosin
backbone, which differs from human b-cardiac myosin
by 83 amino acids in the motor domain alone, whereas
myosin-based HCM and DCM are caused by a single resi-
due change in the protein. This issue is highlighted by the
findings that the same HCM-causing mutation can cause
opposite effects on cardiac power output, depending on
the mouse myosin isoform (a versus b) into which it is
introduced (43). Recent studies of human biopsy specimens
showed decreased force production in cardiomyocytes
from patients carrying HCM-causing b-cardiac myosin
mutations, arguing that loss of contractile function underlies
the development of HCM (44). However, these samples
were obtained from patients undergoing palliative surgery
for severe hypertrophy and contained severely diseased
myocardium with a multitude of secondary changes that
make determining the primary effects of the mutations on
the molecular biomechanics of the sarcomere difficult, if
not impossible.
Taken together, these studies illustrate the great need to
quantify the effect of HCM and DCM mutations on human
cardiac myosin power generation using ensembles of highly
purified and homogeneous human b-cardiac myosin. As
a major advance, Srikakulam and Winkelmann (45) solved
the problem of mammalian myosin expression using adeno-
virus expression in the mouse myogenic cell line C2C12.
They have characterized the involvement of a number of
chaperones involved in mammalian skeletal myosin folding,
including heat shock protein 90 (Hsp90), constitutively ex-
pressed heat shock-related protein 70 (Hsc70), and Unc45b
(45,46). The C2C12 expression system has been adapted to
the cardiomyopathy problem by Deacon et al. (47) andBiophysical Journal 106(6) 1236–1249Resnicow et al. (48), and it is now possible to express human
b-cardiac myosin carrying HCM- and DCM-causing muta-
tions of interest (49,50). Having the human reconstituted
system now provides an opportunity to understand the
detailed effects of these mutations on the power output of
the fundamental unit of the human cardiac muscle, the
sarcomere.
The major goal in my laboratory, as of this writing, is to
understand at the molecular level, with purified reconsti-
tuted components that include human b-cardiac myosin,
the detailed effects of HCM and DCM mutations on the
power output by that molecular assembly. We are using a
variety of assays, including loaded in vitro motility assays
and single-molecule analyses with a dual-beam laser trap.
Because there are currently insufficient data to conclude
that HCMmutations generally cause hypercontractile sarco-
meres and DCM mutations generally cause hypocontractile
sarcomeres at the earliest stages before apparent clinical
symptoms, I will simply refer throughout to mutations
causing increased power output by the sarcomere (hyper-
contractile) versus those causing decreased power output
(hypocontractile). Furthermore, I will focus on mutations
that cause hypercontractility to explain the changes in the
actin-activated myosin chemomechanical cycle that can
lead to increased power output. As you will see, there are
more than two mechanistic buckets, but still a limited num-
ber, probably <10. I will then discuss available assays for
exploring this space, and how they can be used to search
for appropriate small molecule therapies. All that I discuss
below applies to the hypocontractile mutations as well,
but in reverse.Power output is the product of force and velocity
and hypercontractile-causing mutations can
change the F-v curve in two fundamental ways
Fig. 1 d illustrates two mechanistically distinct buckets for
hypercontractile-causing mutations. An increase in power
output could result from an increase in the ensemble force
(red solid line) produced by the muscle, or an increase in
velocity of contraction (green solid line) at various loads.
A combination of change in force and change in velocity
is also possible. Note that small changes in the F-v curve
result in significant changes in power output. Load in
Fig. 1 is the afterload on the muscle, as discussed above.
I refer to the force produced by the cardiac muscle as the
ensemble force, because each myosin head is an indepen-
dent force generator with its own intrinsic force, and the
total force produced in the muscle is the intrinsic force times
the number of heads in the ensemble that are in a force-pro-
ducing state, as described in more detail below.
From a therapeutic point of view, it may be beneficial to
target the increased power output caused by hypercontrac-
tile-causing mutations by developing small molecule inhib-
itors of the power output, regardless of whether those
Biomechanics of Inherited Cardiomyopathy 1239molecules reduce the force or the velocity. Furthermore, one
could target any of the members of the fundamental six-
component contractile system to do so. An agent is likely
to be beneficial simply by bringing the F-v curve back
down toward normal without worrying about its detailed
shape. Ideal small molecule therapies, however, would
normalize the F-v curve across all loads, bringing the
mutant curves in line with the wild-type F-v relationship.
Is this possible? Fortunately, the contractile system is one
of the most thoroughly studied enzyme systems in biology,
so our deep knowledge of the biochemical and biophysical
parameters involved allows the creation of appropriate as-
says for identifying small molecules that independently
modulate F or v.Examination of the actin-activated myosin
chemomechanical cycle suggests several
mechanisms by which hypercontractile-causing
mutations can produce increased power output
The actin-activated myosin chemomechanical cycle can be
divided into two fundamental parts:
1. The weakly-bound state of the myosin heads (yellow,
Fig. 2; the affinity constant in this case is low and one
generally refers to this state as being dissociated from
the actin), with ATP or ADP.Pi bound to the active site
of the motor domain; and
2. The strongly-bound state that is force-producing (red,
Fig. 2).
The fraction of the myosin heads in the sarcomere bound to
actin in the strongly-bound state at any moment is called theFIGURE 2 The actin-activated myosin chemomechanical cycle. Step 1:
ATP binding to the strongly-bound myosin head dissociates it from the
actin. Step 2: ATP hydrolysis is associated with locking the weakly-bound
head into a prestroke configuration. Step 3 (a and b): Rebinding of the head
to actin in a strongly-bound state is associated with Pi release from the
active site. Step 4: After strong binding of the myosin to the actin, the
myosin undergoes an ~10-nm power stroke. The head is now in a
strongly-bound force-producing state and cannot bind ATP until the ADP
is released from the active site. Step 5: ADP is released, allowing rapid
ATP binding, and the cycle continues. Modified from Lymn and Taylor
(95,96). To see this figure in color, go online.‘‘duty ratio’’. In vitro assays show that under very low load,
~5–10% of the human b-cardiac myosin heads are strongly
bound to actin in a force-producing state at any moment dur-
ing the chemomechanical cycle, whereas ~90–95% are get-
ting ready to attach to replace heads that are cycling off (49)
(see also Howard (51) and Uyeda et al. (52)). I will use the
value 0.1 for the duty ratio under very low load for the con-
siderations in this review. As noted above, every head acts as
an independent force generator, producing its own intrinsic
force (f). Therefore, the ensemble force (Fe) produced by the
contractile apparatus is the intrinsic force of each head
multiplied by the total number of heads that are bound in
a force-producing state,
Fe ¼ f ½duty ratio  Nt; (1)
where Nt is the total number of myosin heads overlapping
with the actin thin filaments in the muscle.
A large DG change occurs when ATP binds to the
strongly-bound actin-myosin complex (Step 1, Fig. 2), and
therefore the equilibrium of this step is very far to the right.
Kinetically, ATP binding is extremely fast, as is the resultant
dissociation of the myosin-ATP complex from the actin.
After the myosin head dissociates from actin, hydrolysis is
generally rapid (Step 2, Fig. 2), although slower in cardiac
muscle than in skeletal muscle (50). There is a very small
DG change upon hydrolysis with the ADP and Pi remaining
in the active site, and therefore the equilibrium constant of
this step is an important consideration (see below). For
cardiac myosin, it is thought to favor the ADP.Pi state by
~5:1 (53).
The transition from the myosin-ADP-Pi weakly-bound
(to actin) state to the strongly-bound ADP state (Step 3, a
and b, Fig. 2), involving concomitant release of the Pi
from the active site, is a key transition in the cycle. The
rate of this weak-to-strong transition is generally the rate-
limiting step in the entire cycle and therefore determines
the kcat, or maximum rate of the myosin ATPase activity
at saturating actin concentration (although the ATP hydroly-
sis rate is slow enough for cardiac myosin to potentially
play a role in determination of the kcat). There is a large
DG change across this weak-to-strong transition as a result
of the major increase in affinity of the myosin for actin, and
therefore the equilibrium of this transition is very far to the
right.
Kinetically, this bimolecular interaction of myosin with
actin in the sarcomere is limited by two factors. One is the
kinetic efficiency of the system or how many collisions
need to happen before a productive collision occurs. The
other is that in the sarcomere, the actin thin filament helical
period is different from that of the myosin head arrangement
along the thick filament, and therefore, at any particular
amount of overlap of the thin and thick filaments, only
selected myosin heads see the actin monomer to which it
wants to bind in an orientation that will allow a productiveBiophysical Journal 106(6) 1236–1249
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for individual heads in the sarcomere, at any particular
amount of overlap of the thin and thick filaments, are
different, and are constantly changing during contraction
as the two filaments slide past one another. This is in
contrast to in vitro experiments with purified proteins in
solution, which provide a measure of kcat for the actin-acti-
vated myosin ATPase at saturating actin concentration in
which all heads behave similarly. The kcat for the actin-acti-
vated myosin ATPase in vitro at 23C is ~10 s1. Thus, the
mean cycle time (tc) is ~100 ms (1/kcat). This corresponds to
a tc of ~20 ms at physiological 37
C, because the Q10 for
the ATPase is between 3 and 4 (49,54). But it is worth keep-
ing in mind that in the sarcomere, at any particular amount
of overlap of the thin and thick filaments, some heads are
structurally more favorably positioned for interaction with
actin in contrast to in solution in vitro, limited only by theFIGURE 3 The structures of the actin filament, myosin thick filament,
and their packing in the sarcomere, drawn to scale. (a) Actin is a single-start
left-handed helix, more commonly described as two protofilaments with a
right-handed twist with a repeat of 72 nm or pseudo-repeat of 36 nm. The
myosin filament, approximately three times thicker, consists of myosin
heads arranged in a three-start right-handed helix. The end-on view is
shown on the right. The periodicities of the actin filament and myosin heads
in the thick filament are not related. (b) Schematic representation of a cross
section of a cardiac sarcomere showing a hexagonal packing of myosin
thick filaments with one actin thin filament at each trigonal position (64).
The packing is quite dense with heads very near the actin even in the resting
state. To see this figure in color, go online.
Biophysical Journal 106(6) 1236–1249catalytic efficiency of the collision complex, whereas other
heads are restricted by an unfavorable orientation for actin
interaction compared to in solution in vitro.
Once the myosin head becomes strongly bound to actin,
at low load the head undergoes a power stroke of ~10 nm
(Step 4, Fig. 2), producing a force in the single piconewton
range (55). Note that while Fig. 2 indicates Pi release pre-
cedes the power stroke, it may occur only after the stroke
occurs; this detail remains the subject of debate. The force-
producing state is maintained until ADP is released from
the head (Step 5, Fig. 2), a first-order process. Thus, in the
presence of physiological concentrations of ATP, the rate of
ADP release determines the mean time that the head remains
in a strongly bound state (ts). Because the ratio of the strongly
bound state time to the total cycle time (ts/tc) determines the
duty ratio in the muscle, we can rewrite Eq. 1 as
Fe ¼ f ½ðts=tcÞ  Nt: (2)
There are only a few ways to change ensemble
force
Hypercontractile-causing mutations that result in a change
in Fe (solid red line, Fig. 1 d) can do so by three mecha-
nisms: by changing the intrinsic force f, the strongly bound
state time ts, or the total cycle time tc (or a combination of
these). There are therefore only a few hypothetical mecha-
nistic buckets for changing the ensemble force and thus
altering the power output. However, power output can also
be increased by an increase in velocity.There are two ways to change unloaded velocity
Unloaded velocity can be thought of as the displacement
caused by the myosin head stroke size (d) divided by the
strongly-bound state time, or v ¼ d/ts (51,56,57) (the veloc-
ity of the relative sliding of the actin and myosin filaments
cannot be any faster than the heads can let go of the actin),
although the situation is a bit more complicated due to inter-
actions of heads with one another in an ensemble (see, for
example, Walcott et al. (58)). For simplicity here, consider
that hypercontractile-causing mutations that alter velocity
(solid green line, Fig. 1 d) can do so by modifying the
step size d or the strongly bound state time ts. Changing d
or ts represent two hypothetical mechanistic buckets for
affecting the velocity and thus altering the power output.
So, there are at least four hypothetical mechanistic
buckets for causing an increase in power output by hyper-
contractile-causing mutations, changes in f, ts, tc, or d (or
some combination of these). Alterations in ts are interesting
because such changes have opposing effects on velocity and
ensemble force. Thus, an increase in ts can lead to a decrease
in velocity (decreased power) but an increase in duty ratio
(increased power), and a decrease in ts can lead to
the reverse. Thus, a hypercontractile-causing mutation that
Biomechanics of Inherited Cardiomyopathy 1241leads primarily to a decrease in ts would resemble the green
solid line curve in Fig. 1 d, but the line would cross over the
normal black curve and be below it at higher loads, due
to having a diminished ensemble force to overcome load.
The converse considerations apply to the same three mech-
anistic buckets that can lead to the reduced power output of
hypocontractile-causing mutations.How does the single cycle shown in Fig. 2 play out
in the sarcomere?
How many myosin heads are in a strongly-bound state to an
individual actin filament in the sarcomere at any given time?
And how many times does an individual head go through its
chemomechanical cycle in the course of a single contraction
of the cardiac muscle (systole)? The answers surprised
me and require a reasonably accurate view of the structure
of the sarcomere. There are many published drawings of a
sarcomere to illustrate the sliding filament model of muscle
contraction, but they seldom depict the actin and myosin
drawn to scale, and the conventional textbook schematic rep-
resentations show a much higher extent of shortening than
occurs in human cardiac sarcomeres. The cardiac sarcomere
length at rest (in diastole) is variable in heart muscle, but is
generally reported to be ~2 mm (Fig. 4, top, depicts a 2-mm-
long sarcomere at the beginning of its contraction). The actin
filaments in cardiac muscle have been reported to be 0.8-mm-
long (59) or variable in length in the 1-mm range (59–61)
(Fig. 4 depicts 0.8-mm-long actin filaments, which corre-
sponds to ~22 pseudo-repeats (36 nm each) of the actin
left-handed single-start helix, often described as a right-
handed, two-stranded helical structure).
The cardiacmyosin thick filaments are 1.6-mmlong, 20-nm
wide, and are bipolar, with the myosin tails packing together
in an almost cylindrical backbone and theheads projecting out
laterally in a helical or quasihelical fashion (62,63) (Fig. 3 aand Fig. 4). The bare zone where there are no heads is 0.2
mm. Basically, the cardiac thick filament consists of a three-
start right-handed helical array of myosin heads with a ~40
rotation and a vertical spacing of 14.3 nm between heads
along the helices (Fig. 3 a). Reconstructions from electron
micrographs have revealed perturbations in axial displace-
ment, azimuthal displacement, and tilt of the heads in the
cardiacmyosin filament, but the radial perturbation ofmyosin
heads is minor (62). There are three myosin molecules per
14.3 nm, or nine myosin molecules per 42.9-nm repeat.
If we simplify the thick filament helical array to a cylin-
der, myosin heads along one edge are spaced 42.9-nm apart.
A common packing pattern has each actin filament in the
sarcomere surrounded by three myosin thick filaments,
which are arranged in a hexameric cross-sectional pattern
(Fig. 3 b) (64). In this arrangement, 42.9-nm-spaced heads
from each of three myosin filaments are available to interact
with one actin filament (Fig. 3 b), which corresponds to a
spacing along the actin of approximately one two-headed
myosin molecule every 14.3 nm. Because the myosin thick
filament in a half-sarcomere is 800-nm long, 100 nm of
which is bare zone without heads, and there are three
double-headed myosin molecules every 42.9 nm pointing
toward a given actin filament, then (700/42.9)  3 ¼ ~50
myosin molecules per half-sarcomere are pointing directly
at one actin filament. Other heads that are nearby could
also potentially interact, making the number of heads poten-
tially available for interaction with one actin filament some-
what larger (Figs. 3 and 4), but for simplicity, I will consider
50 myosin molecules per half-sarcomere available for one
actin filament. Note that the periodicity of heads along the
thick filament is different from the periodicity of the actin
filament (36-nm pseudo-repeat), insuring asynchronous
binding of myosin heads to get a smooth contraction.
Although the myosin molecule is two-headed, as depicted
in Fig. 3, Fig. 4 depicts only single heads projecting from theFIGURE 4 Schematic description of a cardiac
sarcomere drawn to scale. (Top) A sarcomere is de-
picted at its resting length just beginning its
contraction. The sarcomere is 2-mm long, the
myosin bipolar thick filaments are 1.6-mm long,
and the actin filaments are 0.8-mm long. The total
number of myosin molecules that an individual
actin filament sees is ~50; only 32 are shown
here because the myosin molecules from the third
thick filament that is out of the plane of focus here
are not shown. Note the myosin molecules are de-
picted as single-headed for simplicity. A duty ratio
of 0.1 is depicted. Thus, ~10% of the myosin mol-
ecules are in a force-producing state (red). (Bot-
tom) The sarcomere has shortened by ~20%. To
see this figure in color, go online.
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key study, Cooke and Franks in 1978 (65) showed that sin-
gle-headed myosin generates one-half as much tension per
molecule as does double-headed myosin. These experiments
conclusively showed that the two heads of myosin interact
independently with actin in the generation of tension, with
no evidence of cooperativity between the heads. These ex-
periments also showed that all the heads in the native two-
headed myosin configuration are available for producing
force because twice the force was observed with the two-
headed myosin than with the single-headed myosin. There-
fore, in my discussions below, I will consider all the myosin
heads (two times the number of myosin molecules) as being
available for force production.
Another simplification in the two-dimensional drawing of
Fig. 4 is that myosin molecules from only two of the three
myosin thick filaments surrounding an individual actin fila-
ment are shown, again for simplicity, which means that there
are ~30% more myosin molecules to interact with a given
actin filament than illustrated in Fig. 4. Despite these simpli-
fications, several key features become apparent from this
figure, as described in more detail below:
1. Even before contraction, the actin and myosin filaments
in cardiac muscle are almost completely overlapping.
2. At very low load, a duty ratio of 0.1 would mean that
each actin would be experiencing the action of <5
myosin molecules at any moment, although this duty
ratio increases as a function of load.
3. An individual myosin molecule in the sarcomere may
only go through one power stroke in the course of sys-
tolic contraction and that myosin does not need to even
undergo one entire ATPase cycle.
The percent shortening of the cardiac sarcomere during
contraction is reported to be quite small, 10–20% (66–68)
(Fig. 4 depicts a 20% shortening). A 20% shortening corre-
sponds to only 10% for each half-sarcomere, or ~200 nm.
Interestingly, even if one considers the left ventricular
chamber of the heart as a simple sphere and assumes a
20% reduction of its circumference (2pr), the volume of
the left ventricle (4pr3/3) would decrease to ~50% after
contraction, close to the ejection fraction of the normal hu-
man heart (~50–70%) (69). The heart is of course not a
sphere, and the effect of its complicated geometry on ejec-
tion fraction and contraction mechanics has been studied
extensively (70–72).
The weakly-bound ADP-Pi-heads in the sarcomere
(yellow in Figs. 2 and 4) are shown as well as the
strongly-bound force-producing ADP-heads (red in Figs. 2
and 4). My surprise upon constructing this diagram was
that even before contraction, the actin and myosin filaments
in cardiac muscle are almost completely overlapping (top,
Fig. 4). Most textbook depictions of sarcomere contraction
suggest that as sliding occurs, more heads are overlapping
with the actin filaments and so more of a contractile forceBiophysical Journal 106(6) 1236–1249is experienced as contraction proceeds (Eq. 2). Note from
Fig. 4, however, that in cardiac muscle there may be only
a modest increase in the number of myosin heads overlap-
ping with actin filaments as contraction occurs.
The velocity of contraction of the heart once the aortic
valve opens, just following isovolumetric contraction, is
dictated by the relevant F-v curve (e.g., see Fig. 1 b).
Assuming the system is designed for shortening of the
sarcomeres to occur at maximum power output, such
velocity should be in the range of 30–60% of maximum
velocity at very low load (Fig. 1 b). The maximum velocity
should reflect the in vitro motility velocity values,
which are obtained under very low load. The velocity of
cardiac muscle contraction under load at 37C is in the
range of ~200-nm full contraction per half-sarcomere
(Fig. 4) in ~200 ms, the duration of the systolic ejection
time (73–75), or ~1 mm s1. If we assume that the
unloaded velocity should be 2–3 times that value, the
unloaded in vitro motility velocity is expected to be
2–3 mm s1 at 37C. Mean values we have obtained
for the in vitro velocity of human b-cardiac myosin are
0.8 mm s1 at 23C and 1.1 mm s1 at 30C (49).
Maximum values, which I would argue more accurately
reflect what occurs in the highly-ordered sarcomeres of
the muscle, are just above 1 mm s1 at 23C (49). Thus
at 37C we expect an unloaded maximum in vitro velocity
approaching 2–3 mm s1, consistent with the prediction
from the actual cardiac shortening velocity.
Systole begins when the left ventricle is full of blood and
the heart undergoes an isovolumetric contraction. At this
stage, the load increases rapidly while little sliding occurs.
In fact, the cardiac muscle is never in a state of very low
load, and load on the muscle (forces acting in the opposing
direction of actin filament sliding) prevents the heads from
undergoing their complete structural transition to a post-
stroke state (end of Step 4, Fig. 2), which slows ADP release
(Step 5, Fig. 2) and prolongs ts. Thus, load changes the duty
ratio (ts/tc) and more heads are bound in a force-producing
state as load is increased. This is the basis of the F-v curve
for muscle—as the load increases, force increases and
velocity decreases. As discussed above, the velocity of
contraction of the heart once the aortic valve opens is
dictated by the relevant F-v curve, and the actual velocity
of contraction is likely to be 30–60% of the maximum
unloaded velocity. A velocity of 30% of maximum corre-
sponds to a threefold reduction in ts and therefore a threefold
increase in duty ratio. Considering a duty ratio of 0.1 at very
low load, the duty ratio may increase to 0.3. A threefold
increase in duty ratio corresponds to three times the number
of heads bound in a strongly bound state than at very low
load. As apparent from Fig. 4, which corresponds to a
very low load state, this corresponds to an increase from
~5 myosin molecules per actin filament to ~15 myosin
molecules in a strongly-bound force-producing state, still
a fairly small number.
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one power stroke in the course of systolic
contraction
Another interesting consideration illuminated by Fig. 4
relates to the number of chemomechanical cycles (Fig. 2)
that a particular myosin head goes through, per systolic
contraction. The fundamental unit of the myofibril is the
half-sarcomere. All of the actin filaments in the half-sarco-
mere are linked by way of their attachment to a common Z-
line (structure consisting of a-actinin and other components
that bind to the (þ)-end of actin filaments). Cross-sections
through the myofibrils of cardiomyocytes show that sarco-
mere sizes in cardiac muscle are variable, ranging from
~100 to ~1000 actin filaments in one half-sarcomere ar-
ranged in a hexagonal array. Each actin filament is directly
associated with ~50 myosin molecules, and any movement
along any individual actin filament will contribute to pulling
all of the linked actin filaments toward the center of the
myosin thick filaments. Considering an average of 500 actin
filaments in a half-sarcomere, there are a total of ~25,000
myosin molecules in a single average-sized half-sarcomere
pointing directly at the actin filaments.
Any myosin heads that are not strongly bound to actin
(Fig. 2, yellow) have already bound ATP and are in equilib-
rium with their ADP.Pi-bound prestroke heads. As noted
above, equilibrium may favor the ADP.Pi state by as much
as ~5:1 (53). Thus, as the actin filaments encounter these
heads, strong actin binding is the trigger that fires these
cocked guns to undergo a step of ~10 nm per head. If load
were negligible, not many heads would be needed of the
25,000 in the half-sarcomere to complete the half-sarcomere
shortening depicted in Fig. 4 of ~200 nm; only ~20 heads pro-
ducing a stroke of 10 nm each would suffice. The muscle is
not, of course, ever under negligible load. Twenty heads in
the half-sarcomere would not overcome the load that exists
in the system.
I already indicated that there are ~50 double-headed
myosin molecules directly poised to interact with a single
actin filament in the half-sarcomere. The actual number of
heads that can interact is <100 for two reasons:
1. At any moment many heads are not oriented properly
to bind the actin helical filament due to the different
symmetries of the thin actin-containing filaments and
the thick myosin-containing filaments, and must await
some filament sliding to bring an actin monomer into
favorable orientation.
2. Any heads with ATP bound rather than ADP.Pi are un-
able to bind. Thus, the equilibrium constant at Step 2
of Fig. 2 is important. If the two states are distributed
1:5, then 80% of the heads are available, but if they
were distributed 1:1, then only 50% of the heads would
be available. An HCM or DCM mutation or small-mole-
cule-potential drug that affects this equilibrium constant
will impact force production.Given these considerations, there are probably <50 myosin
molecules available for interaction with a single actin fila-
ment in a half-sarcomere. Even if we assume all 50 mole-
cules are available, as already discussed above, the duty
ratio under load is likely to increase by a factor of ~3,
such that ~15 myosin molecules per actin filament would
be in a strongly-bound force-producing state, out of the 50
myosin molecules present. Because only ~20 strokes of
~10 nm each are required to traverse the 200 nm of sliding,
it seems possible that no head would have to stroke more
than once. This view is supported by the realization that
the ATPase chemomechanical cycle time under physiolog-
ical conditions of temperature and load (~50–100 ms) is
not very different from the systolic ejection time of the
normal heart beat (73). Thus, there is little time for heads
that have fired to recock and rebind in a strongly-bound state
again before systole is finished.
These considerations also mean that an interacting head
does not need to undergo one entire ATPase cycle because
it would be starting in the cocked ADP.Pi state and its effect
ends essentially upon ADP release, at which time ATP
rapidly binds and allows the head to dissociate from the
actin. Thus, a potential drug that affects the kinetics or the
thermodynamics of the head may only have to apply its
effect to this single partial cycle of activity during each
systolic contraction.Is the hypothesis that myosin binding to actin
facilitates the Ca2D response during contraction
physiologically relevant?
My beginnings in the muscle field was 1969, when I had the
great fortune to spend two years as a postdoctoral fellow at
the Medical Research Council Laboratory of Molecular
Biology in Cambridge, England, working with Hugh Hux-
ley. There I reconstituted the six-component Ca2þ-regulated
actin-myosin-tropomyosin-troponin C,I,T system and car-
ried out biochemical and structural studies that led us to
propose the steric-blocking mechanism for tropomyosin-
troponin function (76,77). In the absence of Ca2þ, the
troponin complex holds tropomyosin in a position on the
actin filament that blocks the myosin interaction with actin
(i.e., the blocked state (78)). To initiate systole, Ca2þ
released from the sarcoplasmic reticulum binds to troponin
C, which allosterically, through troponin I and troponin T,
releases tropomyosin from its blocked state, allowing
myosin to interact with actin.
It is often suggested that myosin binding to actin has a
cooperative effect on moving the tropomyosin out of its
inhibitory state, and that it is a combination of Ca2þ binding
to troponin C and myosin binding to actin that is involved
in systole (see review by Moss et al. (79)). This sugges-
tion derives from in vitro studies with the reconstituted
six-component system and with detergent-permeabilized
cardiomyocytes. If one examines those data for how muchBiophysical Journal 106(6) 1236–1249
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tropomyosin movement, it is a relatively high number—
~1 myosin head for every seven actin monomers. The con-
siderations discussed above suggest that even under load,
only ~15 myosin molecules per 0.8-mm-long actin filament
are in a strongly-bound force-producing state; that corre-
sponds to, at most, 30 myosin heads per ~290 actin mono-
mers, or 1 myosin head per ~10 actin monomers. Thus,
the physiological significance for heart muscle contraction
of the in vitro observed myosin-binding-induced tropomy-
osin movement must be questioned. Consistent with this,
Sun et al. (80) present studies that suggest that although
myosin binding can switch on thin filaments in rigor condi-
tions, it does not contribute significantly under physiolog-
ical conditions, and that the physiological mechanism of
cooperative Ca2þ regulation of cardiac contractility must
be intrinsic to the thin filaments.FIGURE 5 Assay for activation of myosin ATPase activity by the regu-
lated actin thin filament as a function of free Ca2þ concentration. The
in vitro generated curves mimic well the expected pCa range operating in
cardiac muscle (gray zone); actually, under normal everyday conditions
of behavior, the human heart seldom reaches even halfway up this curve.
The two mutations shown are troponin T mutations and the assays were car-ASSAYS ARE AVAILABLE TO ASSESS THE
FUNDAMENTAL PARAMETERS THAT LEAD TO AN
INCREASE IN POWER OUTPUT
Fortunately, assays with purified sarcomeric proteins are
available to explicitly explore the parameters f, ts, tc, and
d, and see how they change in a particular HCM or DCM
mutant.ried out using expressed human b-cardiac myosin S1 (data from Sommese
et al. (82)). To see this figure in color, go online.
Steady-state actin-activated myosin ATPase
activity
The simplest and longest-standing biochemical assay is
actin-activated ATPase activity, which follows Michaelis-
Menten kinetics to give the maximum ATPase rate at satu-
rating actin concentration (kcat for the cycle) and the Km
or apparent affinity for myosin binding to actin. As dis-
cussed above, the mean cycle time tc falls directly out of
this assay because tc ¼ 1/kcat.The ATPase assay extended: pCa curves to assay
regulation by the tropomyosin-troponin complex
As mentioned earlier, in cardiac muscle the actin-myosin
interaction is regulated through the Ca2þ sensitivity of the
thin filament. Cardiac muscle is in its resting state (diastole)
when Ca2þ concentration is <107 M (pCa < 7) and un-
dergoes contraction when Ca2þ is released from the sarco-
plasmic reticulum and binds to TnC in the sarcomere,
which removes the steric block of the actin binding site
for myosin. The normal operating range in cardiac muscle
under normal conditions is from a pCa of ~7 to a pCa of
~6 (Fig. 5).
There are a variety of assays for examining the effects
of HCM- and DCM-causing mutations on the Ca2þ regula-
tion of the actin-myosin interaction. A favorite and
standard assay is to measure the ATPase of the six-compo-Biophysical Journal 106(6) 1236–1249nent system (actin, myosin, tropomyosin, and troponins T,
I, and C) as a function of Ca2þ concentration, commonly
referred to as a pCa curve (36,40,81,82). This assay can
be applied to studies of HCM and DCM mutations in hu-
man b-cardiac myosin, but has most often been used to
study the regulatory proteins carrying HCM and DCM mu-
tations. Numerous studies show, for example, that troponin
mutations shift this pCa curve to the left in the case of
HCM mutations and to the right in the case of DCM
mutations (36,40,81,82) (Fig. 5). Shifting the curve to
the left sensitizes the system to Ca2þ and results in a
higher ATPase during systole (suggesting hypercontractil-
ity) and a failure to relax completely at a pCa of 7
(a diastolic problem, consistent with the HCM clinical syn-
drome). Shifting the curve to the right desensitizes the sys-
tem to Ca2þ and results in a lower ATPase during systole
(suggesting hypocontractility, consistent with the DCM
clinical syndrome).
Whereas this assay is very powerful, it, like all in vitro as-
says, has its limitations. It is difficult to carry out this assay
in saturating concentrations of regulated thin filaments, and
therefore the activity changes observed at maximal activa-
tion may result from changes in the Km of myosin binding
to the thin filament, rather than changes in kcat. Km changes
may not be very relevant to the function of the muscle,
Biomechanics of Inherited Cardiomyopathy 1245where the concentrations of the sarcomeric proteins are
extremely high. Furthermore, steady-state ATPase only re-
lates to changes in tc, which is only one variable in deter-
mining power output. One must use a combination of all
the assays discussed here to understand changes in all the
four important parameters, f, tc, ts, and d, to get the complete
picture of the effects of the HCM or DCM mutation of
interest.FIGURE 6 In vitro motility taken to the single-molecule level. (a)
Myosin-coated surfaces drive the movement of fluorescently-labeled actin
filaments at velocities comparable to those of muscle contraction (85).
(b) The dual-beam laser-trap assay for measuring nanometer steps and pi-
conewton forces of a single myosin molecule (55). (c) Force transients
measured by clamping the position of the actin-bound polystyrene bead
on the left (purple, in panel b) as the myosin is trying to move the actin
to the right. (d) Mean intrinsic forces from multiple preparations of wild-
type human b-cardiac myosin S1 (black circles) and human b-cardiac
myosin S1 carrying the HCM-causing mutation R453C (red circles) (49).
To see this figure in color, go online.Transient kinetic assays
Transient kinetic assays comprise a powerful set of tools in
muscle research (83). There are specific assays that allow
one to measure the kinetics of essentially every step in the
chemomechanical cycle. From the discussion above, a crit-
ical step for cardiac myosin is the ADP release rate, because
that rate determines ts, and changes in ts lead to a change in
duty ratio as well as a change in velocity, both of which
affect power output. One assay for the ADP release
rate utilizes pyrene-labeled actin, which demonstrates
an approximately twofold decrease in fluorescence upon
myosin binding. If one rapidly mixes saturating ATP with
a preformed actin-b-cardiac myosin S1 complex, an
extremely fast dissociation rate of myosin from the actin
(~1000 s1 at 20C, Step 1, Fig. 2) can be measured
by following the increase of fluorescence as a function
of time (47). Because the ADP release rate from an
actin-myosin-ADP complex is comparatively very slow
(~100 s1 at 20C), one can preload ADP onto an actin-
myosin complex before adding saturating ATP. The ATP
cannot bind to and release the myosin from the actin (Step
1, Fig. 2) until the ADP comes out of the pocket (Step 5,
Fig. 2), and therefore the rate of fluorescence change be-
comes a readout of the rate of ADP dissociation. This is
one way to estimate ts. In this experiment, the contractile
system is under zero load.
For several decades, actin-activated ATPase and transient
kinetic assays were the primary in vitro quantitative assays
for the actin-activated myosin chemomechanical cycle,
completely focused on the chemo aspect and ignoring the
mechanical part of the cycle.In vitro motility assay
In the 1980s, quantitative in vitro motility assays with pu-
rified actin and myosin were established (17,84,85) that
gave a velocity readout that mimicked closely the veloc-
ities of muscle contraction (Fig. 6 a). The values obtained
for velocity by this method are key, and relate to ts and d,
as described above. Importantly, one can apply load to
moving actin filaments by adding an actin-binding protein
to the surface, which then opposes the force being applied
to the filament by the myosin molecules (49,86–89). This
allows one to generate a load-velocity curve by measuring
the decrease of velocity as a function of increasingconcentration of the load-producing protein. This is an
extremely powerful tool, because with three purified pro-
teins—actin, myosin, and the load-producing protein—
one can measure the differences in the force-velocity
curves shown in Fig. 1.The single-molecule, dual-beam laser-trap assay
for measuring nanometer steps and piconewton
forces
None of the above assays allow direct measurement of the
intrinsic force f or the step size d. Values for these parame-
ters can be obtained using the dual-beam, single-molecule
laser-trap assay developed in the 1990s (55). I like to refer
to this assay as a simplified in vitro motility assay, because
as is apparent in Fig. 6, the assay is the same, but simplifiedBiophysical Journal 106(6) 1236–1249
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perched on a polystyrene bead fixed to the surface and inter-
acting with a single actin filament. The actin filament is sus-
pended above the myosin molecule by virtue of being
attached near its ends to two polystyrene beads held in place
by two focused laser beams. The bead is being viewed by a
quadrant detector that is very sensitive to even 1 nm of
movement. One can change the strength by which the
bead on the left of Fig. 6, for example, is held in the trap.
At very low trap force compared to the intrinsic force-pro-
ducing capability of the motor, the stroke size of the motor,
d, can be measured by the displacement of the bead out of
the laser trap.
A powerful feature of the trap is that its strength can be
increased to just match the intrinsic force of the motor. A
feedback circuit in the system increases the strength of the
trap to hold the bead position constant when a myosin inter-
acts with the actin. This is basically an isometric tension
measurement at the single-molecule level. The trap strength
can be calibrated so that one observes force transients rather
than step sizes (Fig. 6 c), and the mean of many molecular
events is the intrinsic force of the motor. Measurement of
the intrinsic force of expressed human b-cardiac myosin
motor domain (subfragment 1 of the myosin or S1; the
head depicted in Figs. 2–4) carrying an HCM-causing muta-
tion (R453C) was obtained only recently (49) and showed
that the mutant myosin has a 50% increase in its intrinsic
force-producing capability (Fig. 6 d).
As apparent in Fig. 6 c, one can also measure how long
the myosin remains bound to the actin under the conditions
used. The data in Fig. 6 c was taken at low ATP concentra-
tion and therefore the mean dwell time is a measure of the
second-order rate constant for ATP binding. Such experi-
ments carried out in saturating ATP concentrations reveal
the ADP release rate and directly measure the strongly-
bound state time ts under physiological conditions of ATP
concentrations. Because ts is related to velocity, one can
generate a F-v curve at the single-molecule level by varying
the force of the trap to obtain a mean ts as a function of force.MUTATIONS CAN BE MIMICKED BY SMALL
MOLECULE EFFECTORS THAT BIND TO THE
CONTRACTILE PROTEINS AND ALTER THEIR
STRUCTURES
Just as single missense mutations slightly alter the structure
of the protein of interest and therefore perturb its function,
the binding of a small molecule to that protein should in
many instances do the same. This is particularly true of a
very allosteric enzyme such as myosin where the actin bind-
ing domain, the nucleotide binding pocket, and the converter
domain are all in exquisite communication with one another.
One example of a cardiac myosin activator is omecamtiv
mecarbil (OM) (90), which is being developed as a treatment
for heart failure characterized primarily by systolic dysfunc-Biophysical Journal 106(6) 1236–1249tion (91,92). OM was discovered in a screen for actin-acti-
vated myosin ATPase activators, and its primary effect on
the chemomechanical cycle shown in Fig. 2 is to increase
the rate of the weak-to-strong transition, resulting in a
decrease in tc. This causes an increase in duty ratio, leading
to an increase in both ensemble force and power output. Un-
derstanding how OM increases the weak-to-strong transition
will require a high-resolution crystal structure of the myosin-
OM complex. OM is known from cross-linking studies to
bind between the nucleotide-binding pocket and the con-
verter domain of the myosin head (90), a primary communi-
cation zone between the active site and the lever arm that
produces the ~10-nm power stroke (Fig. 1). Another example
of a small molecule activator of the contractile apparatus, but
acting by a different mechanism, is tirasemtiv, a fast skeletal
muscle activator. Tirasemtiv is being developed as a potential
treatment for diseases and conditions associated with aging,
muscleweakness andwasting, or neuromuscular dysfunction
(93,94). In this case, the small molecule enhances contrac-
tility through allosteric interactions with the tropomyosin-
troponin regulatory system.
An effort to develop small molecule therapies specifically
for the inherited diseases of the heart discussed in this
review is particularly attractive. In patients with HCM or
DCM, we know that the disease is often caused by a single
residue change in myosin or one of a number of other sarco-
meric proteins, and is heritable as an autosomal dominant,
monogenic Mendelian disease. Importantly, in many cases,
the mutation is clearly the cause of the disease, and if one
understands the effects of a particular amino-acid substitu-
tion on changes in f, ts, tc, and/or d, then it seems likely
that very precise modifiers of power output can be generated
to reverse the effects of that mutation, potentially interrupt-
ing, in the case of HCM, the cascade of events leading to
hypertrophy, diastolic dysfunction, obstruction, and fibrosis
at its source. If this hypothesis, which is eminently testable,
holds true, such therapies are potentially disease modifiers,
and by interrupting the pathogenic cascade, allow the
diseased heart to remodel, which it is very capable of doing.
Although any inhibitor of power output is likely to have a
positive effect on hypercontractile-causing mutations, spe-
cific inhibitors that affect ensemble force (by altering f, ts,
or tc) to reduce power and others that reduce velocity
(by altering ts or d) are likely to be even better. Thus, a small
number of buckets of small molecule inhibitor types married
to the same mechanistic buckets of the hypercontractile-
causing mutations offers an opportunity for a precision med-
icine approach. The same is true for hypocontractile-causing
mutations, except small molecule activators for power
output will be needed.CONCLUSIONS AND FUTURE PERSPECTIVES
As I have described here, in vitro molecular studies of bio-
chemically reconstituted sarcomeric protein complexes are
Biomechanics of Inherited Cardiomyopathy 1247critical for laying the foundation for understanding the
effects of HCM- and DCM-causing mutations on power
generation by the fundamental contractile apparatus of the
sarcomere. With such a detailed understanding at the molec-
ular level, one should be able to exquisitely design and
screen for appropriate small molecule therapies that are
desperately needed for treatment of these diseases.
What might be the best strategy for reducing the increased
power output resulting from hypercontractile-causing muta-
tions? Small molecules that significantly increase the affinity
of myosin for actin should be avoided, for that will inhibit
the relaxation process. The best potential drugs for hypercon-
tractile-causingmutationsmay be those that park some of the
heads in a state that cannot interact with actin. Thus, agents
that shift the equilibrium (Step 2, Fig. 2) between myosi-
n.ATP (which cannot bind to actin) and myosin.ADP.Pi
(which can bind to actin leading to a strongly-bound force-
producing state) toward the myosin.ATP state would reduce
the number of myosin.ADP.Pi heads in the sarcomere avail-
able for the weak-to-strong transition. Similarly, slowing the
rate of the weak-to-strong transition of myosin.ADP.Pi bind-
ing to actin and associated Pi release (Fig. 2, Step 3, a and b)
will increase tc and therefore reduce the duty ratio and, there-
fore, the ensemble force. For those mutations that cause a
decrease in the rate of ADP release, it will be important to
find small molecules that can reverse that effect. This is
because a reduced ADP release rate is expected to cause dia-
stolic problems, inasmuch as the duty ratio would be
increased, causing more heads to be associated with the actin
filaments during systole, and it is therefore likely to take
longer to remove them during diastole.
While I have focused the discussion here on hypercon-
tractile-causing mutations in human b-cardiac myosin, hy-
pocontractile-causing mutations are also of considerable
interest. The above discussion points regarding hypercon-
tractile-causing mutations apply to hypocontractile-causing
mutations as well. Should the paradigm hold true that HCM
mutations cause increased power output of the contractile
apparatus at the sarcomere level, at the earliest stages before
apparent clinical symptoms, whereas DCM mutations cause
decreased power output, one would want small molecule in-
hibitors for HCM and small molecule activators for DCM.
In addition to HCM- and DCM-causing mutations in the
human b-cardiac myosin, mutations in other fundamental
sarcomeric proteins including tropomyosin, the troponins,
myosin-binding protein C, and titin also cause HCM and
DCM. The regulated actin-activated myosin contractile
system is one of the most thoroughly studied systems in
biology, with a multitude of approaches having been applied
to muscle contraction for more than seven decades. Thus, a
deep understanding of the fundamental biochemical and
biophysical basis of action of muscle is on hand. With this
deep understanding, the development of modern therapeu-
tics to directly and specifically target components of the sar-
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